The effect of intermittent IL-2 therapy on CD4 T cells in the gut in HIV-1-infected patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 56, Issue 4, 2011, Pages 340-343

  Read, Sarah W ^a   Ciccone, Emily J ^a   Mannon, Peter J ^b   Yao, Michael D ^a   Chairez, Cheryl L ^a   Davey, Richard T ^a   Kovacs, Joseph A ^c   Sereti, Irini ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b University of Alabama at Birmingham   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

CD4; gastrointestinal tract; HIV; IL 2; mucosa

Indexed keywords

ANTIRETROVIRUS AGENT; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; KI 67 ANTIGEN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL EXPANSION; CLINICAL ARTICLE; COLON BIOPSY; COLON MUCOSA; CONTROLLED STUDY; DRUG INTERMITTENT THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN TISSUE; ILEUM; IMMUNE RESPONSE; INTESTINE MUCOSA; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIGENS, CD2; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; GASTROINTESTINAL TRACT; HIV INFECTIONS; HUMANS; INTERLEUKIN-2; KI-67 ANTIGEN; MIDDLE AGED; TREATMENT OUTCOME;

EID: 79952419159     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31820bf84c     Document Type: Article

References (20)

1. Guadalupe M, Reay E, Sankaran S, et al. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol. 2003;77:11708-11717. (Pubitemid 37271669)
2. Veazey RS, DeMaria M, Chalifoux LV, et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science. 1998;280:427-431. (Pubitemid 28208163)
3. Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004;200:749-759. (Pubitemid 39299461)
4. Anton PA, Elliott J, Poles MA, et al. Enhanced levels of functional HIV-1 co-receptors on human mucosal T cells demonstrated using intestinal biopsy tissue. AIDS. 2000;14:1761-1765.
5. Mehandru S, Poles MA, Tenner-Racz K, et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med. 2004;200: 761-770. (Pubitemid 39299462)
6. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365-1371. (Pubitemid 44924494)
7. Ciccone EJ, Read SW, Mannon PJ, et al. Cycling of gut mucosal CD4+ T cells decreases after prolonged anti-retroviral therapy and is associated with plasma LPS levels. Mucosal Immunol. 2010;3:172-181.
8. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338: 853-860. (Pubitemid 28135961)
9. May MT, Sterne JA, Costagliola D, et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet. 2006;368:451-458.
10. Kovacs JA, Vogel S, Albert JM, et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med. 1996;335:1350-1356. (Pubitemid 26360453)
11. Davey RT Jr, Chaitt DG, Albert JM, et al. A randomized trial of highversus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J Infect Dis. 1999;179: 849-858. (Pubitemid 29159330)
12. Levy Y, Capitant C, Houhou S, et al. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group. Lancet. 1999;353: 1923-1929. (Pubitemid 29255705)
13. Davey RT Jr, Murphy RL, Graziano FM, et al. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: a randomized controlled trial. JAMA. 2000;284:183-189. (Pubitemid 30460861)
14. Kovacs JA, Lempicki RA, Sidorov IA, et al. Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J Clin Invest. 2005;115:2139-2148. (Pubitemid 41134155)
15. Sereti I, Martinez-Wilson H, Metcalf JA, et al. Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4(+)/CD25(+) T cells. Blood. 2002;100:2159-2167. (Pubitemid 35001252)
16. Sereti I, Anthony KB, Martinez-Wilson H, et al. IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. Blood. 2004;104:775-780. (Pubitemid 38970572)
17. Abrams D, Levy Y, Losso MH, et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med. 2009; 361: 1548-1559.
18. Sereti I, Herpin B, Metcalf JA, et al. CD4 T cell expansions are associated with increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV infected patients. AIDS. 2001;15:1765-1775. (Pubitemid 32939236)
19. Smith KA. Interleukin-2: inception, impact, and implications. Science. 1988;240:1169-1176.
20. Porter BO, Shen J, Kovacs JA, et al. Interleukin-2 cycling causes transient increases in high-sensitivity C-reactive protein and D-dimer that are not associated with plasma HIV-RNA levels. AIDS. 2009;23: 2015-2019.